BI 754091

Drug Profile

BI 754091

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Sep 2017 Boehringer Ingelheim initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/ Unresectable, Second-line therapy or greater) in USA (NCT03166631)
  • 13 Jun 2017 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT03156114)
  • 30 May 2017 Boehringer Ingelheim plans a phase I trial of BI 754091 in combination with BI 891065 for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/ Unresectable, Second-line therapy or greater) (NCT03166631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top